Clinical progress and pharmacology of small molecule bromodomain inhibitors

Current Opinion in Chemical Biology

Volumn 33, Issue , 2016, Pages 58-66

  Theodoulou, Natalie H ^a,b   Tomkinson, Nicholas C O ^b   Prinjha, Rab K ^a   Humphreys, Philip G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; APABETALONE; BINDING PROTEIN; BRG1 PROTEIN; BRM PROTEIN; BROMODOMAIN CONTAINING PROTEIN 7; BROMODOMAIN CONTAINING PROTEIN 9; BROMODOMAIN INHIBITOR; CONSERVED ADENOVIRAL E1A BINDING PROTEIN; CP 0610; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MK 8628; POLYBROMO 1 BROMODOMAIN 5; PROTEIN; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; MOLECULAR PROBE;

CLINICAL PHARMACOLOGY; EMBRYO DEVELOPMENT; HUMAN; INFLAMMATION; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; REVIEW; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; MOLECULAR LIBRARY; MOLECULAR MODEL; MOLECULAR PROBE;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR PROBES; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84973523391     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2016.05.028     Document Type: Review

References (54)

1. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Disc 2012, 11:384-400.
2. Zeng L., Li J., Muller M., Yan S., Mujtaba S., Pan C., Wang Z., Zhou M.M. Selective small molecules blocking HIV-1 tat and coactivator PCAF association. J Am Chem Soc 2005, 127:2376-2377.
3. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., White J., Kirilovsky J., Rice C.M., Lora J.M., Prinjha R.K., Lee K., Tarakovsky A.A. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
4. Mirguet O., Gosmini R., Toum J., Clement C.A., Barnathan M., Brusq J.M., Mordaunt J.E., Grimes R.M., Crowe M., Pineau O., Ajakane M., Daugan A., Jeffrey P., Cutler L., Haynes A.C., Smithers N.N., Chung C.W., Bamborough P., Uings I.J., Lewis A., Witherington J., Parr N., Prinjha R.K., Nicodeme E. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem 2013, 56:7501-7515.
5. Chung C.W., Coste H., White J.H., Mirguet O., Wilde J., Gosmini R.L., Delves C., Magny S.M., Woodward R., Hughes S.A., Boursier E.V., Flynn H., Bouillot A.M., Bamborough P., Brusq J.M.G., Gellibert F.J., Jones E.J., Riou A.M., Homes P., Martin S.L., Uings I.J., Toum J., Clement C.A., Boullay A.B., Grimley R.L., Blandel F.M., Prinjha R.K., Lee K., Kirilovsky J., Nicodeme E. Discovery and characterisation of small molecule inhibitors of the BET family bromodomains. J Med Chem 2011, 54:3827-3838.
6. Filippalopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
7. Garnier J.M., Sharp P.P., Burns C.J. BET bromodomain inhibitors: a patent review. Expert Opin Ther Patents 2014, 24:185-199.
8. Gallenkamp D., Gelato K.A., Haendler B., Weinman H. Bromodomains and their pharmacological inhibitors. ChemMedChem 2014, 9:438-464.
9. Jennings L.E., Measures A.R., Wilson B.G., Conway S.J. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. Future Med Chem 2014, 6:179-204.
10. Bamborough P., Chung C.W. Fragments in bromodomain drug discovery. MedChemComm 2015, 6:1587-1604.
11. Brand M., Measures A.R., Wilson B.G., Cortopassi W.A., Alexander R., Höss M., Hewings D.S., Rooney T.P.C., Paton R., Conway S.J. Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS Chem Biol 2015, 10:22-39.
12. Smith S.G., Zhou M.M. The bromodomain: a new target in emerging epigenetic medicine. ACS Chem Biol 2016, 11:598-608.
13. Ferri E., Petosa C., McKenna C.E. Bromodomains: structure, function and pharmacology of inhibition. Biochem Pharmacol 2016, 106:1-18.
14. Romero F.A., Taylor A.M., Crawford T.D., Tsui V., Côté A., Magnuson S. Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 2016, 59:1271-1298.
15. Herait P.E., Berthon C., Thieblemont C., Raffoux E., Magarotoo V., Stathis A., Thomas X., Leleu X., Gomez-Roca C., Odore E., Roumier C., Bourdel F., Quesnel B., Zucca E., Michallet M., Recher C., Cvitkovic E., Rezai K., Preudhomme C., Facon T., Palumbo A., Dombret H. BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Res 2014, 74:CT231.
16. Dombret H., Preudhomme C., Berthon C., Raffoux E., Thomas X., Vey N., Gomez-Roca C., Ethell M., Yee K., Bourdel F., Herait P., Michallet M., Recher C., Roumier C., Quesnel B. A phase 1 study of the BET-bromodomain inhibitor OTX015 in patients with advanced acute leukemia. 56th American Society of Hematology Annual Meeting and Exposition 2014, 117. [December 6-9, Oral abstract].
17. Herait P., Dombret H., Thieblemont C., Facon T., Stathis A., Cunningham D., Palumbo A., Vey N., Michallet M., Recher C., Rezai K., Preudhomme C. BET-bromodomain (BRD) inhibitor OTX015: final results of the dose-finding part of a phase I study in hematologic malignancies. Ann Oncol 2015, 26:ii10-ii11.
18. Odore E., Lokiec F., Cvitkovic E., Bekradda M., Herait P., Bourdel F., Kahatt C., Raffoux E., Stathis A., Thieblemont C., Quesnel B., Cunnigham D., Riveiro M.E., Rezaï K., Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies. Clin Pharmacokinet 2016, 55:397-405.
19. Abramson J.S., Blum K.A., Flinn I.W., Gutierrez M., Goy A., Maris M., Cooper M., O'Mera M., Borger D., Mertz J., Sims R.J., Jeffrey S., Younes A. BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 Study. American Society of Hematology 57th Annual Meeting & Exposition 2015, [December 5-8, 1491 abstract].
20. Shapiro G.I., Dowlati A., LoRusso P.M., Eder J.P., Anderson A., Do K.T., Kagey M.H., Sirard C., Bradner J.E., Landau S.B. Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC). American Association for Cancer Research-National Cancer Institute-European Organsiation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics 2015, [November 5-9, A49, Presentation Abstract].
21. Shortt J., Hsu A.K., Martin B.P., Doggett K., Matthews G.M., Doyle M.A., Ellul J., Jockel T.E., Andrews D.M., Hogg S.J., Reitsma A., Faulkner D., Bergsagel P.L., Chesi M., Heath J.K., Denny W.A., Thompson P.E., Neeson P.J., Ritchie D.S., McArthur G.A., Johnstone R.W. The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. Cell Reports 2014, 7:1009-1101.
22. McLure K.G., Gesner E.M., Tsujikawa L., Kharenko O.A., Attwell S., Campeau E., Wasiak S., Stein A., White A., Fontano E., Suto R.K., Wong N.C., Wagner G.S., Hansen H.C., Young P.R. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLOS ONE 2013, 8:e83190.
23. Picaud S., Wells C., Felletar I., Brotherton D., Martin S., Savitsky P., Diez-Dacal B., Philpott M., Bountra C., Lingard H., Fedorov O., Müller S., Brennan P.E., Knapp S. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A 2013, 110:19754-19759.
24. Apabetalone/RVX-208 Clinical Development 2016, Resverlogix, Calgary, http://www.resverlogix.com/programs/rvx-208-clinical-development/#.VpPEj79kfOw [accessed 08.01.16].
25. Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE November 2016, Resverlogix, Calgary, http://www.resverlogix.com/media/press-release.html?id=534#.Vo-lpr9kfOw2015 [accessed 08.01.16].
26. Bunnage M.E., Piatnitski Chekler E.L., Jones L.H. Target validation using chemical probes. Nat Chem Biol 2013, 9:195-199.
27. Sweis R.F. Target (in)validation: a critical, sometimes unheralded, role of modern medicinal chemistry. ACS Med Chem Lett 2015, 6:618-621.
28. Theodoulou N.H., Tomkinson N.C.O., Prinjha R.K., Humphreys P.G. Progress in the development of non-BET bromodomain chemical probes. ChemMedChem 2016, 11:477-487.
29. Hohmann A.F., Vakoc C.R. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet 2014, 30:356-363.
30. Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H., Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol 2010, 58:380-389.
31. Guetzoyan L., Ingham R.J., Nikbin N., Rossignol J., Wolling M., Baumert M., Burgess-Brown N.A., Strain-Damerell C.M., Shrestha L., Brennan P.E., Fedorov O., Knapp S., Ley S.V. Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography. MedChemComm 2014, 5:540-546.
32. Picaud S., Strocchia M., Terracciano S., Lauro G., Mendez J., Daniels D.L., Riccio R., Bifulco G., Bruno I., Fillipakopoulos P. 9H-Purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem 2015, 58:2718-2736.
33. Hay D.A., Rogers C.M., Fedorov O., Tallant C., Martin S., Monteiro O.P., Müller S., Knapp S., Schofield C.J., Brennan P.E. Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains. MedChemComm 2015, 6:1381-1386.
34. Theodoulou N.H., Bamborough P., Bannister A.J., Becher I., Bit R.A., Che K.H., Chung C.W., Dittmann A., Drewes G., Drewry D.H., Gordon L., Grandi P., Leveridge M., Lindon M., Michon A.M., Molnar J., Robson S.C., Tomkinson N.C.O., Kouzarides T., Prinjha R.K., Humphreys P.G. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J Med Chem 2016, 59:1425-1439.
35. Mirguet O., Lamotte Y., Donche F., Toum J., Gellibert F., Bouillot A., Gosmini R., Nguyen V.L., Delannee D., Seal J., Blandel F., Boullay A.B., Boursier E., Martin S., Brusq J.M., Krysa G., Riou A., Tellier R., Costaz A., Huet P., Dudit Y., Trottet L., Kirilovsky J., Nicodeme E. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg Med Chem Lett 2012, 22:2963-2967.
36. Clark P.G., Vieira L.C., Tallant C., Fedorov O., Singleton D.C., Rogers C.M., Monteiro O.P., Bennett J.M., Baronio R., Müller S., Daniels D.L., Méndez J., Knapp S., Brennan P.E., Dixon D.J. LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor. Angew Chem Int Ed Engl 2015, 54:6217-6221.
37. Tough D.F., Prinjha R.K., Tak P.P. Epigenetic mechanisms and drug discovery in rheumatology. Clin Med 2015, 15:s64-s71.
38. Albrecht BK, Cote A, Crawford T, Benjamin F, Huang HR, Lora JM, Magnuson S, Nasveschuk CG, Salmeron A, Sims III RJ, Taylor AM: Treating Th2-mediated diseases by inhibition of bromodomains. WO2014144721A2.
39. Iyer N.G., Özdag H., Caldas C. p300/CBP and cancer. Oncogene 2004, 23:4225-4231.
40. Matt T. Transcriptional control of the inflammatory response: a role for the CREB-binding protein (CBP). Acta Med Aust 2002, 29:77-79.
41. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998, 93:361-372.
42. Sachchidanand, Resnick-Silverman L., Yan S., Mutjaba S., Liu W.J., Zeng L., Manfredi J.J., Zhou M.M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 2006, 13:81-90.
43. Borah J.C., Mujtaba S., Karakikes I., Zeng L., Muller M., Patel J., Moshkina N., Morohashi K., Zhang W., Gerona-Navarro G., Hajjar R.J., Zhou M.M. A small molecule binding to the co-activator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol 2011, 18:531-541.
44. Hewings D.S., Wang M., Philpott M., Fedorov O., Uttarkar S., Filippakopoulos P., Picaud S., Vuppusetty C., Marsden B., Knapp S., Conway S.J., Heightman T.D. 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 2011, 54:6761-6770.
45. Unzue A., Xu M., Dong J., Wiedmer L., Spiliopoulos D., Caflisch A., Nevado C. Fragment-based design of selective nanomolar ligands of the CREBBP bromodomain. J Med Chem 2016, 59:1350-1356.
46. Hay D.A., Fedorov O., Martin S., Singleton D.C., Tallant C., Wells C., Picaud S., Philpott M., Monteiro O.P., Rogers C.M., Conway S.J., Rooney T.P.C., Tumber A., Yapp C., Filippakopoulos P., Bunnage M.E., Müller S., Knapp S., Schofield C.J., Brennan P.E. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 2014, 136:9308-9319.
47. Hammitzsch A., Tallant C., Fedorov O., O'Mahony A., Brennan P.E., Hay D.A., Martinez F.O., Al-Mossawi M.H., de Wit J., Vecellio M., Wells C., Wordsworth P., Müller S., Knapp S., Bowness P. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. PNAS 2015, 112:10768-10773.
48. Piatnitski Chekler E.L., Pellegrino J.A., Lanz T.A., Aldrin Denny R., Flick A.C., Coe J., Langille J., Basak A., Liu S., Stock I.A., Sahasrabudhe P., Bonin P.D., Lee K., Pletcher M.T., Jones L.H. Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem Biol 2015, 22:1588-1596.
49. Picaud S., Fedorov O., Thanasopoulou A., Leonards K., Jones K., Meier J., Olzscha H., Monteiro O., Martin S., Philpott M., Tumber A., Filippakopoulos P., Yapp C., Wells C., Hing Che K., Bannister A., Robson S., Kumar U., Parr N., Lee K., Lugo D., Jeffrey P., Taylor S., Vecellio M.L., Bountra C., Brennan P., O'Mahony A., Velichko S., Muller S., Hay D., Daniels D.L., Urh M., La Thangue N.B., Kouzarides T., Prinjha R., Schwaller J., Knapp S. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res 2015, 75:5106-5541.
50. Albrecht BK, Audia JE, Bellon S, Andrea C, Cote A, Crawford T, Fauber B, Ghosh S, Harmanage JC, Hatzivassiliou G, Jayaram H, Kim J, Lora JM, Magnuson S, Mellman I, Romero FA, Taylor AM, Tsui V: Use of CBP/EP300 bromodomain inhibitors for cancer immunotherapy. WP2015054642A2.
51. Medina P.P., Carretero J., Fraga M.F., Esteller M., Sidransky D., Sanchez-Cespedes M. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Gene Chromosome Cancer 2004, 41:170-177.
52. Ortega S.S., Balinas C., Cuadros M., Medina P.P. SWI/SNF proteins as targets in cancer therapy. J Hematol Oncol 2014, 7:81-84.
53. Fedorov O., Castex J., Tallant C., Owen D.R., Martin S., Aldeghi M., Monteiro O., Filippakopoulos P., Picaud S., Trzupek J.D., Gerstenberger B.S., Bountra C., Willmann D., Wells C., Philpott M., Rogers C., Biggin P.C., Brennan P.E., Bunnage M.E., Schüle R., Günther T., Knapp S., Müller S. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv 2015, 1:e1500723.
54. Vangamudi B., Paul T.A., Shah P.K., Kost-Alimova M., Nottebaum L., Shi X., Zhan Y., Leo E., Mahadeshwar H.S., Protopopov A., Futreal A., Tieu T.N., Peoples M., Heffernan T.P., Marszalek J.R., Toniatti C., Petrocchi A., Verhelle D., Owen D.R., Draetta G., Jones P., Palmer W.S., Sharma S., Andersen J.N. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res 2015, 75:3865-3878.